About Regulus Therapeutics
Regulus Therapeutics is a Healthcare company based in San Diego (United States) founded in 2007, and was acquired by Novartis in April 2025. Developing microRNA-based therapeutics for oncology, infectious, fibrosis and metabolic diseases. Regulus Therapeutics has raised $35 million across 11 funding rounds from investors including Alnylam, Novartis and RA Capital. The company has 30 employees. Regulus Therapeutics offers products and services including Farabursen and Pipeline Programs. Its focus areas include Life Sciences, Gene Therapy, RNA and miRNA. Its competitors include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Regulus Therapeutics was founded in 2007 and is headquartered in San Diego, United States. Focus is placed on the discovery and development of microRNA-based therapeutics targeting diseases such as hepatitis C, Alport syndrome, oncology, fibrosis, and metabolic disorders. Specific candidates like RG-101 for hepatitis C and RG-012 for Alport syndrome are advanced, alongside programs in partnership for oncology and fibrosis. Operations involve inhibiting upregulated microRNAs involved in disease states.
- Headquarters San Diego, United States
- Employees 30
- Stage Acquired
- SectorsHealthcare
- Website regulusrx.com
- Social LinkedIn X
- Acquired by Novartis (Apr 2025)
- Legal Name Regulus Therapeutics
- Annual Revenue$10.01 M (USD)46as on Dec 31, 2020
- Net Profit-$46.36 M (USD)-54as on Dec 31, 2024
- EBITDA-$50.04 M (USD)-61as on Dec 31, 2024
- Total Equity Funding$35M (USD)
in 11 rounds
- Latest Funding Round$100M (USD), Post-IPO
Mar 2024
- InvestorsAlnylam
& 9 more
- Employee Count30
- Acquired byNovartis
(Apr 2025)
Products & Services of Regulus Therapeutics
Regulus Therapeutics offers a comprehensive portfolio of products and services, including Farabursen and Pipeline Programs.
MicroRNA-based treatment for autosomal dominant polycystic kidney disease.
Develops novel approaches for high unmet need kidney diseases.
Funding Insights of Regulus Therapeutics
Regulus Therapeutics has successfully raised a total of $35M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35M
- Total Rounds 11
- Last Round Post-IPO — $100M
- First Round $20M
(Mar 2009)
- Investors Count 9
Latest 10 of 11 funding rounds of Regulus Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $100M | Post-IPO | – | – | |
| Apr 2023 | $15M | Post-IPO | – | – | |
| Nov 2021 | $34.62M | Post-IPO | – | – | |
| Dec 2020 | $19.38M | Post-IPO | – | – | – |
| May 2019 | $16.74M | Post-IPO | – | – | – |
| Jun 2017 | Post-IPO | – | – | ||
| Feb 2014 | $10M | Post-IPO | – | – | – |
| Oct 2012 | $25M | Post-IPO | – | – | – |
| Aug 2012 | $5M | Series A | – | – | – |
| Oct 2010 | $10M | Series A | – | – | – |
10 investors in total: 10 institutional.
Investors in Regulus Therapeutics
Regulus Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Alnylam, Novartis and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
Investments in healthcare startups are managed by Octagon Capital Advisors. | octagoninvestments.com | New York, United States | ||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Investment management services are provided to institutional and retail clients. | 1955 | federatedhermes.com | Pittsburgh, United States | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | alnylam.com | Cambridge, United States | |
Ionis Pharmaceuticals is focused on RNA- and DNA-targeted medicines. | 1989 | ionispharma.com | Carlsbad, United States | |
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Regulus Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Regulus Therapeutics
24 people are tracked at Regulus Therapeutics (9 in leadership, 8 in board & advisors, 7 in team); the tracked headcount is 30.
| Name | Role | Group |
|---|---|---|
Jay Hagan | President & CEO | Leadership |
Cris Calsada | CFO | Leadership |
Daniel Penksa | Vice President, Finance & Controller | Leadership |
Preston S. Klassen | President & Head of Reserach & Development | Leadership |
Curtis Monnig | VP & CMC | Leadership |
Firuz Shakoori | Head Of GMP Manufacturing & Supply | Leadership |
Brian Campion | VP, Business Development | Leadership |
Morgan Carlson | VP, Biology | Leadership |
Edmund Lee | VP, Translational Medicine | Leadership |
Pascale Witz | Director | Board & advisors |
Jake R. Nunn | Director | Board & advisors |
Hugh Rosen | Director | Board & advisors |
Kathryn L. Collier | Director | Board & advisors |
Stelios Papadopoulos | Chairman | Board & advisors |
David Baltimore | Director | Board & advisors |
William H. Rastetter | Director | Board & advisors |
Alice S. Huang | Director | Board & advisors |
Christopher Aker | SVP & General Counsel | Team |
Claire Padgett | SVP, Clinical Operations | Team |
James Nilsen | Sr. Accountant, Financial Reporting & SOX Compliance | Team |
4 more people are available in the full profile.
Complete people profiles for Regulus Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Regulus Therapeutics
5 dated milestones of Regulus Therapeutics across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Regulus Therapeutics is founded.
- Funding First funding round of $20.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $100.0M.
- Exit Acquired by Novartis.
Competitors of Regulus Therapeutics
Regulus Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. |
Detailed competitors of Regulus Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Regulus Therapeutics
Websites that share an audience with Regulus Therapeutics (regulusrx.com).
Websites whose visitors overlap most with Regulus Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
isispharm.com | isispharm.com | 100% | – | ||
| biopharminternational.com | 97% | 55.1K | #674,468 | View details | |
| rousselet-robatel.com | 68% | 1.2K | #12,201,754 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Regulus Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Regulus Therapeutics
Complete news archive for Regulus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Regulus Therapeutics
Regulus Therapeutics was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Regulus Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Regulus Therapeutics is a funded company, having raised a total of $35M across 11 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Mar 2009.
Regulus Therapeutics has 30 employees.
Annual revenue of Regulus Therapeutics is $10.01M as on Dec 31, 2020.
Regulus Therapeutics was founded in 2007 and is headquartered in San Diego, United States. Focus is placed on the discovery and development of microRNA-based therapeutics targeting diseases such as hepatitis C, Alport syndrome, oncology, fibrosis, and metabolic disorders. Specific candidates like RG-101 for hepatitis C and RG-012 for Alport syndrome are advanced, alongside programs in partnership for oncology and fibrosis. Operations involve inhibiting upregulated microRNAs involved in disease states.
Regulus Therapeutics's top competitors include Poseida Therapeutics, Denali Therapeutics and Castle Biosciences.
Regulus Therapeutics offers Farabursen and Pipeline Programs.
Regulus Therapeutics has 10 investors. Key investors include Alnylam, Novartis, RA Capital, Federated Hermes, and NEA.
Regulus Therapeutics operates through Regulus Therapeutics.
Yes. Regulus Therapeutics was acquired by Novartis in April 2025.